The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus
By BZ Group
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by BZ Group
Category: Life Sciences
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 2
Reviews: 0
Episodes: 66
Description
Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Weekend Edition every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, pharma industry deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for professionals who need to stay ahead.
Hosts voices are AI created
| Episode | Date |
|---|---|
|
May 20, 2026 | Pfizer's Next-Gen Pneumonia Vaccine Beats Prevnar 20; BMS Deploys Anthropic AI
|
May 21, 2026 |
|
May 19, 2026 | Takeda $885M Antitrust Verdict; Bimzelx Beats Skyrizi in PsA Head-to-Head
|
May 21, 2026 |
|
May 18, 2026 | Regeneron LAG-3 Phase 3 Failure Crashes Stock 11%; Supreme Court Cements IRA
|
May 19, 2026 |
|
May 15, 2026 | FDA's CDER Chief Høeg Expected to Exit; Tecentriq Wins Bladder Cancer Approval
|
May 17, 2026 |
|
May 14, 2026 | AstraZeneca Imfinzi Phase 3 Win in Bladder Cancer; Gene Therapy Safety Overhang
|
May 15, 2026 |
|
May 13, 2026 | BeOne's Beqalzi Wins FDA Approval, Breaking BCL-2 Monopoly; Takeda Cuts 4,500 Jobs
|
May 14, 2026 |
|
May 12, 2026 | FDA Commissioner Makary Resigns; BMS-Hengrui $15.2B 13-Asset Alliance
|
May 13, 2026 |
|
May 11, 2026 | CSL Flags $5B Vifor Impairment as Shares Hit Nine-Year Low
|
May 12, 2026 |
|
May 10, 2026 | Vyvgart Wins Broadest gMG Label; Merck Closes $6.7B Terns Deal
|
May 11, 2026 |
|
May 08, 2026 | Trump Plans to Fire FDA Commissioner Makary; Leqembi SC Delayed to August
|
May 09, 2026 |
|
May 07, 2026 | Angelini's $4.1B Catalyst Buyout; Atara Surges 40% on FDA Path Forward; Roche Acquires PathAI
|
May 08, 2026 |
|
May 06, 2026 | Bayer Acquires Perfuse for $2.45B in Ophthalmology; Novo Wegovy Pill Posts $355M Q1
|
May 07, 2026 |
|
May 05, 2026 | Cytokinetics Cracks Non-Obstructive HCM; Pfizer's $2.3B Trillium Write-Off
|
May 05, 2026 |
|
May 04, 2026 | SCOTUS Restores Mifepristone Mail Access; First PROTAC Drug Wins FDA Approval
|
May 05, 2026 |
|
May 03, 2026 | UCB's $2.2B Candid Therapeutics Deal; FDA Moves to Withdraw Tavneos
|
May 04, 2026 |
|
May 01, 2026 | FDA Approves First PROTAC Drug Veppanu; Pharma M&A Hits $84B in Q1; Truqap Clears ODAC 7-1
|
May 04, 2026 |
|
Apr 28, 2026 | Erasca Crashes 48% on Patient Death; Lilly's $2.3B Ajax Deal
|
Apr 29, 2026 |
|
Apr 27, 2026 | Sun Pharma just wrote an eleven-point-seven-five billion dollar check to acquire Organon
|
Apr 28, 2026 |
|
Apr 24, 2026 | Foundayo Trails Oral Wegovy 5-to-1 in Week 2; Inhibrx Draws $6.7B
|
Apr 25, 2026 |
|
Apr 23, 2026 | Regeneron's Otarmeni Approved as First Gene Therapy for Hearing Loss
|
Apr 24, 2026 |
|
Apr 21, 2026 | Merck Welireg Fails First-Line Kidney Cancer; Lilly's $7B Kelonia CAR-T
|
Apr 22, 2026 |
|
Apr 20, 2026 | Lilly's $7B Kelonia In Vivo CAR-T Bet; TIGIT Fails Again at Gilead-Arcus
|
Apr 21, 2026 |
|
Apr 19, 2026 | Allogene's Off-the-Shelf CAR-T Clears Futility Bar; Kailera Prices $625M IPO
|
Apr 21, 2026 |
|
Apr 16, 2026 | Lilly Foundayo Clears Heart Safety for Diabetes Filing; Cochrane Calls Amyloid Drugs 'Trivial'
|
Apr 17, 2026 |
|
Apr 15, 2026 | J&J Q1 Earnings Beat on Tremfya Growth; Revolution Medicines $2B Raise
|
Apr 16, 2026 |
|
Apr 14, 2026 | Daraxonrasib Nearly Doubles Pancreatic Cancer Survival; Neurocrine-Soleno $2.9B Deal
|
Apr 14, 2026 |
|
Apr 12, 2026 | FDA Rejects Replimune RP1 Again; Sun Pharma's $12B Organon Bid; Amgen TEPEZZA Subcutaneous Win
|
Apr 13, 2026 |
|
Apr 09, 2026 | Lilly Launches Oral GLP-1 Foundayo; Gilead's $3.15B Tubulis ADC Acquisition
|
Apr 09, 2026 |
|
Apr 07, 2026 | Pharma Tariffs Hit 100% with Major Loopholes; Gilead's $3.15B Tubulis ADC Deal
|
Apr 08, 2026 |
|
Apr 06, 2026 | Gilead's $3.15B Tubulis ADC Deal; Neurocrine's $2.9B Prader-Willi Bet
|
Apr 08, 2026 |
|
Apr 05, 2026 | Lilly Foundayo vs Novo Oral Wegovy Launch War; Trump Signs 100% Pharma Tariff
|
Apr 06, 2026 |
|
Apr 03, 2026 | Trump's 100% Drug Tariffs Reshape Pharma; $25.5B M&A Spree
|
Apr 04, 2026 |
|
Apr 02, 2026 | Trump's 100% Drug Tariff Splits Pharma; Lilly Foundayo Approved
|
Apr 03, 2026 |
|
Apr 01, 2026 | FDA Approves Lilly's Foundayo Oral Obesity Pill; Immunovant Batoclimab Fails Phase 3 TED Trials
|
Apr 02, 2026 |
|
Mar 31, 2026 | Lilly's $7.8B Centessa Deal; Biogen Buys Apellis for $5.6B; FDA Flags Tavneos Deaths | Mar 31, 2026
|
Apr 01, 2026 |
|
Mar 30, 2026 | Tyvaso's Second Phase 3 Win in IPF; Viridian Crashes 38% on TED Data
|
Mar 31, 2026 |
|
Mar 29, 2026 | Lilly's $2.75B AI Drug Deal with Insilico; Oral Psoriasis Data Reshapes Derm at AAD 2026
|
Mar 30, 2026 |
|
Mar 27, 2026 | Novo Nordisk's Once-Weekly Insulin Awiqli Wins FDA Approval; $15B+ in Pharma Deals
|
Mar 28, 2026 |
|
Mar 26, 2026 | Wave Crashes 58% on Obesity Data Miss; CVC Bids $12.6B for Recordati
|
Mar 27, 2026 |
|
Mar 25, 2026 | Merck's $6.7B Terns Acquisition for CML Drug TERN-701
|
Mar 26, 2026 |
|
Mar 24, 2026 | ImmunityBio's Third FDA Warning Letter; Gilead Bets $1.68B on Ouro Medicines Autoimmune Bispecifi...
|
Mar 25, 2026 |
|
Mar 23, 2026 | Apogee Eczema Data Sends Stock Up 20%; Gilead Nears $2B Ouro Medicines Deal
|
Mar 23, 2026 |
|
Mar 22, 2026 | Abbott's $21B Exact Sciences Deal Closes; Wegovy HD Approved, Orforglipron Delayed
|
Mar 23, 2026 |
|
Mar 20, 2026 | Novartis $2B Bet on PI3Kα in Breast Cancer; Opdivo Approved for Hodgkin Lymphoma
|
Mar 21, 2026 |
|
Mar 19, 2026 | Lilly Retatrutide Phase 3 Clears All Endpoints; FDA Approves Wegovy HD in 54 Days
|
Mar 20, 2026 |
|
Mar 18, 2026 | FDA Approves J&J's Oral Psoriasis Pill Icotyde; Bicycle Therapeutics Cuts 30% of Workforce
|
Mar 18, 2026 |
|
Mar 17, 2026 | Aldeyra's Third FDA Rejection Crashes Stock 68%; CytomX Masked ADC Surges 60%
|
Mar 18, 2026 |
|
Mar 16, 2026 | Structure Therapeutics Oral GLP-1 Data Rivals Orforglipron; BioMarin Halts Voxzogo Studies
|
Mar 17, 2026 |
|
Mar 15, 2026 | Immutep LAG-3 Phase 3 Failure Crashes Stock 88%; Ultragenyx Gene Therapy Hits OTc
|
Mar 16, 2026 |
|
Mar 13, 2026 | GSK Arexvy Expands to At-Risk Adults 18-49; Novartis Cosentyx Pediatric HS Approval
|
Mar 14, 2026 |
|
Mar 12, 2026 | Ultragenyx Gene Therapy Hits Phase 3 Endpoint; Lilly's $3B China Bet; LAG-3 Oncology Setback
|
Mar 13, 2026 |
|
The AI Reckoning — Episode 4: Who Wins
|
Mar 12, 2026 |
|
Mar 11, 2026 | Vertex Kidney Drug Hits Phase 3; Lilly's $3B China Expansion; UCB Bimzelx Beats Skyrizi
|
Mar 12, 2026 |
|
Mar 10, 2026 | BioNTech's co-founders just walked away
|
Mar 11, 2026 |
|
Mar 09, 2026 | Novo Nordisk Partners with Hims on GLP-1 Distribution; BMS Wins Sotyktu PsA Approval
|
Mar 10, 2026 |
|
The AI Reckoning — Episode 3: The Agentic Enterprise
|
Mar 09, 2026 |
|
Weekend Round Up March 08, 2026: Gilead's $7.8B CAR-T Bet; Servier Acquires Day One for $2.5B
|
Mar 09, 2026 |
|
Mar 06, 2026 | FDA not convinced AMT-130 works; Moderna +14% on melanoma data; Servier’s $2.5B Day One bet
|
Mar 07, 2026 |
|
Mar 5, 2026 | Theravance Phase 3 CYPRESS Failure Triggers 50% Workforce Cut, Science CoRaises $230M for Retinal BCI + Sotyktu PsA PDUFA Tomorrow
|
Mar 06, 2026 |
|
Mar 4, 2026 | Moderna’s $2.25B LNP Patent Settlement, FDA Fires 30 GLP-1 Compounding Warning Letters + Sotyktu PsA PDUFA Friday
|
Mar 06, 2026 |
|
Special Series| AI Reckoning Ep 2: From Molecule to Market — 173 AI Drugs in Trials, But Phase 2 Data Tells a Different Story
|
Mar 05, 2026 |
|
Mar 3, 2026 | Novo’s $506M Oral GLP-1 Manufacturing Bet, Sotyktu PsA PDUFA Friday, Orforglipron Race Begins
|
Mar 03, 2026 |
|
Mar 2, 2026 | Gilead’s $7.8B CAR-T Bet, YUVIWEL Approved, PADCEV-Keytruda Resets Bladder Cancer
|
Mar 03, 2026 |
|
Mar 1, 2026 | CagriSema Week of Reckoning: Analysts Revise, Novo Regroups | YUVIWEL Approved + PRV Voucher | Weekend Edition
|
Mar 03, 2026 |
|
Feb 27, 2026 | CagriSema's New Story After REDEFINE 4, GSK's $950M Activin Bet, Lilly Wins ACHIEVE-3
|
Mar 03, 2026 |
|
Special Series| AI Reckoning Ep 1: The Reckoning — 5% of Pharma Has AI Advantage, 95% Still Running Pilots
|
Mar 02, 2026 |